Compounded veterinary medications carry distinct legal obligations and safety risks that differ meaningfully from FDA-approved products.

Legal use requires a valid veterinarian-client-patient relationship as a baseline condition. Compounding is permitted only when a veterinarian concludes that a compounded drug — rather than a preexisting approved product — is necessary for an animal with a diagnosed medical condition.Journal of the… The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) governs this framework, and compounding from bulk drug substances is explicitly prohibited under AMDUCA.Journal of the… The FDA defines compounding as any manipulation of a drug beyond what is included on the FDA-approved label, including mixing two or more approved drugs into a single dosing form, altering physical form (e.g., crushing tablets), adding flavoring, or creating formulations from bulk chemical ingredients.Journal of the…

Compounding from bulk active pharmaceutical ingredients is illegal but subject to enforcement discretion under specific conditions. The FDA may waive enforcement when the drug is intended for a specific nonfood animal, is distinguishable from any comparable FDA-approved drug in ways that produce a clinical difference, is produced in the absence of an FDA-approved alternative, is compounded in accordance with U.S. Pharmacopeial Convention standards, is made from bulk ingredients produced in registered establishments accompanied by a certificate of analysis, and is labeled with the species, patient name, and owner name — with serious adverse events reported to the FDA within 15 days.Journal of the… Gabapentin, for example, is not listed as an accepted bulk chemical ingredient in FDA draft guidance GFI #256, meaning compounding it from bulk substances falls outside this framework even when USP chapter 795 standards are otherwise followed.Journal of Feli…

Potency variability is a documented and clinically significant safety risk. Compounded chlorambucil potency ranged from 71–104% of labeled strength, and compounded melphalan ranged from 58–109%, with one-quarter of chlorambucil samples and one-quarter of melphalan samples falling below 90% of labeled strength at baseline — rising to two-quarters of samples for both drugs at six weeks.Veterinary and… Compounded cyclophosphamide performed better, ranging from 92–107% with all samples within ±10% of labeled strength at all time points.Veterinary and… Compounded doxycycline chew formulations should be avoided entirely based on potency data, and splitting scored compounded doxycycline tablets produces drug content variability that places a larger proportion of split pieces outside the acceptable range.Journal of the…

Stability beyond-use dates require documented scientific validation. Compounded doxycycline formulations assigned beyond-use dates exceeding 7 days after preparation require evidence of stability obtained through valid scientific methods.Journal of the… Without such data, clinicians cannot assume that labeled concentrations are maintained throughout the dispensing period.

Bioavailability of compounded formulations can differ substantially from FDA-approved products, with direct efficacy consequences. Compounded liquid sildenafil made from bulk powder — rather than from an FDA-approved finished drug product — showed variable absorption that likely contributed to lack of efficacy in dogs with megaesophagus.American Journa… Compounded levetiracetam extended-release tablets achieved bioequivalence to the commercial formulation only when produced by a 503B outsourcing facility using specific excipients (Methocel K100M and silicified microcrystalline cellulose); products compounded by other pharmacies require independent testing before use can be recommended.Journal of Vete… Compounded apomorphine administered via the transconjunctival route achieved emesis in only 16% of dogs within 10 minutes, compared to substantially higher success rates via intravenous and intranasal routes.Journal of the…

Facilities operating under Section 503B of the Federal Food, Drug, and Cosmetic Act are subject to more stringent oversight than 503A pharmacies, and sourcing compounded products from 503B outsourcing facilities mitigates — though does not eliminate — concerns about identity, quality, strength, purity, and stability.Journal of Vete…

In food-producing and wildlife species, additional restrictions apply. Compounded drugs from FDA-approved products may be used in food-producing animals only when AMDUCA and legal compounding requirements are met; pharmacokinetic data generally do not exist for compounded drugs, making it difficult or impossible to calculate a scientifically based withdrawal interval.Journal of the… In exotic animal practice, extralabel use and compounding are essential given the scarcity of FDA-approved drugs for exotic species, but the same legal framework applies.Veterinary Clin…

For equine practitioners, three conditions should govern the decision to prescribe a compounded medication: the decision must be evidence-based within a valid veterinarian-client-patient relationship; AMDUCA must be followed; and use should be limited to horses for which no other delivery method is practical, drugs for which safety, efficacy, and stability have been demonstrated, or conditions for which a quantifiable therapeutic response or drug concentration can be monitored.Veterinary Clin…

Would you like guidance on how to evaluate whether a specific compounded formulation meets the stability and potency standards required before prescribing it?